AlphaStocks
5.6
Consider Buy

Protagonist Therapeutics, Inc (PTGX)

Health Care / Biotechnology

S&P SmallCap 600

$103.79

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 2 of 5 models — limited data

#414out of 1127 in Health Care

Is Protagonist Therapeutics, Inc a Good Investment in 2026?

Protagonist Therapeutics, Inc (PTGX) scores 5.6 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating Protagonist Therapeutics, Inc as Neutral. However, the Graham model rates it Caution. Protagonist Therapeutics, Inc ranks #414 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-12.1Market Cap7B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Limited Data

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Protagonist Therapeutics, Inc (PTGX) a good investment?
Based on AlphaStocks' composite analysis, Protagonist Therapeutics, Inc (PTGX) scores 5.6 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Currently unprofitable — fair value estimate not available.
What is Protagonist Therapeutics, Inc's Piotroski F-Score?
Protagonist Therapeutics, Inc's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PTGX overvalued or undervalued?
A precise fair value estimate is not available for PTGX. Currently unprofitable — fair value estimate not available.
How does PTGX compare to other Health Care stocks?
Protagonist Therapeutics, Inc ranks #414 out of 1127 stocks in the Health Care sector, placing it in the top 37% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about PTGX?
AlphaStocks evaluates PTGX using five proven investment models. Piotroski: Neutral; Graham: Caution. These models are combined into a single composite score of 5.6/10.

Similar Stocks

PARRFTIAZN

Compare PTGX with

PTGX vs PARRPTGX vs FTIPTGX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer